What's in a name? An emerging framework for cancer-associated fibroblasts, myofibroblasts, and fibroblasts

Cancer Cell. 2022 Nov 14;40(11):1273-1275. doi: 10.1016/j.ccell.2022.10.018.


In this issue of Cancer Cell, Foster and colleagues explore the heterogeneity in cancer-associated fibroblasts (CAFs) across tissue types and species, and they identify mechanoresponsive (MR), immunomodulatory (IM), and steady-state-like (SSL) CAFs. They show that altering the relative abundance of these CAF subtypes influences tumor progression and response to anti-tumor therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Cancer-Associated Fibroblasts*
  • Fibroblasts
  • Humans
  • Myofibroblasts
  • Neoplasms* / pathology
  • Tumor Microenvironment

Grants and funding